BG
NTLA icon

Bellevue Group’s Intellia Therapeutics NTLA Stock Holding History

Bellevue Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,978
Closed -$26.8K – 182
2025
Q4 		$26.8K Buy
+2,978
New +$41K ﹤0.01% 175
2022
Q4 		– Sell
-30,478
Closed -$1.71M – 176
2022
Q3 		$1.71M Buy
30,478
+14,684
+93% +$911K 0.02% 125
2022
Q2 		$817K Sell
15,794
-500
-3% -$25.4K 0.01% 141
2022
Q1 		$1.18M Sell
16,294
-300
-2% -$25.4K 0.01% 143
2021
Q4 		$1.96M Hold
16,594
– – 0.02% 147
2021
Q3 		$2.23M Buy
+16,594
New +$2.51M 0.02% 145
2019
Q1 		– Sell
-15,834
Closed -$216K – 146
2018
Q4 		$216K Sell
15,834
-600
-4% -$11.2K 0.01% 137
2018
Q3 		$470K Sell
16,434
-300
-2% -$8.73K 0.03% 137
2018
Q2 		$458K Buy
+16,734
New +$405K 0.04% 134

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bellevue Group's NTLA Position: Q1 2026 in Review

Bellevue Group sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 2,978 shares — an estimated $26.8K sold.

Bellevue Group first reported a position in NTLA in Q2 2018 and held it in 9 quarters. The position peaked at $2.23M in Q3 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Bellevue Group reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 2,978 Intellia Therapeutics shares in Q1 2026, an estimated $26.8K.
  • Bellevue Group first reported a position in Intellia Therapeutics in Q2 2018 and held it in 9 quarters.
  • Bellevue Group's Intellia Therapeutics position peaked at $2.23M in Q3 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.